Urinary Problems in Men — Causes, Symptoms & Treatment Guide — Symptoms, Causes & Treatment | MyMedicPlus

Lower urinary tract symptoms (LUTS) encompass a range of urinary symptoms affecting storage (frequency, urgency, nocturia, incontinence) and voiding (hesitancy, poor stream, intermittency, straining, incomplete emptying). They affect approximately 30% of men over 50 and are increasingly common with age. The most common cause is benign prostatic hyperplasia (BPH) — non-malignant enlargement of the prostate gland — which gradually obstructs the bladder outlet. Other causes include overactive bladder (OAB), urethral stricture, detrusor underactivity, urinary tract infection, and prostate or bladder cancer. LUTS from BPH is generally a progressive condition, but severity fluctuates and spontaneous improvement occurs in some men. The International Prostate Symptom Score (IPSS) — a validated 7-question questionnaire scoring symptom severity from 0 to 35 — is used to assess and monitor LUTS and guide treatment decisions. Differentiating BPH from urological malignancy is essential — prostate-specific antigen (PSA) testing and digital rectal examination are integral to assessment.

Benign prostatic hyperplasia (BPH): the most common cause of LUTS in men over 50. Results from proliferation of stromal and epithelial cells in the transitional zone of the prostate under the influence of dihydrotestosterone (DHT — converted from testosterone by 5-alpha-reductase). The enlarged gland compresses the urethra, increasing bladder outlet resistance, causing obstructive voiding symptoms and secondary detrusor overactivity (storage symptoms). Risk factors for BPH: advancing age (the primary factor), genetic predisposition (first-degree relative with BPH — 4x risk), obesity, metabolic syndrome, diabetes, and sedentary lifestyle. Overactive bladder (OAB): storage symptoms (urgency, frequency, nocturia) without outflow obstruction — caused by detrusor overactivity, neurological disorders (stroke, Parkinson's, multiple sclerosis), or idiopathic. Urethral stricture: narrowing of the urethra from prior infection (gonococcal), catheterisation, or trauma — causes voiding LUTS. Prostate cancer: must always be considered and excluded in men with new LUTS — particularly if PSA is elevated or there is a palpably hard or nodular prostate on DRE. Bladder stones: may cause LUTS and haematuria — can form secondary to BPH-related urinary stasis. Neurogenic bladder: from diabetes mellitus (diabetic cystopathy — impaired detrusor sensation and contractility), spinal cord injury, multiple sclerosis, or Parkinson's disease.

Voiding (obstructive) symptoms: hesitancy (difficulty initiating urination — waiting for flow to begin), poor urinary stream (weak, thin, slow stream), intermittent stream (flow starting and stopping), straining to pass urine, sensation of incomplete bladder emptying, post-micturition dribble (dribbling of urine after voiding), and prolonged voiding time. Storage (irritative) symptoms: urinary frequency (voiding more than 8 times per day), nocturia (waking 2 or more times at night to void — most bothersome symptom in older men), urgency (sudden compelling desire to void), and urgency urinary incontinence (leakage associated with urgency). Acute urinary retention (AUR): sudden inability to pass urine — painful, tense, palpably distended bladder requiring emergency catheterisation; may be precipitated by alcohol, constipation, anticholinergic drugs, or urinary tract infection. Complications of long-standing LUTS/BPH: recurrent UTIs (from post-void residual urine), bladder stones (urinary stasis), hydronephrosis and renal impairment (chronic urinary retention causing back-pressure on kidneys), and chronic urinary retention (painless distension — may require long-term catheterisation or surgery).

Clinical assessment: IPSS questionnaire (International Prostate Symptom Score) — categorises LUTS as mild (0-7), moderate (8-19), or severe (20-35); bladder diary (frequency-volume chart) over 3 days — documents voiding frequency, volumes, urgency episodes, and fluid intake; digital rectal examination (DRE) — assesses prostate size, consistency, and symmetry (hard or nodular — suspect prostate cancer). Prostate-specific antigen (PSA) blood test: discussed with the patient (PSA testing and screening): elevated PSA (above age-specific threshold) may indicate BPH, prostatitis, or prostate cancer — the PSA result always requires interpretation in clinical context. PSA above 3 ng/mL in men over 50 with LUTS warrants urology review. Urinalysis and urine culture: excludes UTI and haematuria as contributing causes. Renal function (U+E, eGFR): if chronic urinary retention or upper tract involvement is suspected. Urinary flow rate (uroflowmetry): peak flow rate (Qmax) — normal above 15 mL/s; below 10 mL/s suggests outflow obstruction. Post-void residual urine (PVR) bladder scan: measured by portable ultrasound; above 200-300 mL suggests impaired bladder emptying. Flexible cystoscopy: visualises the urethra and bladder interior — excludes urethral stricture, bladder stones, and bladder tumour. Urodynamics (pressure-flow studies): for men with suspected neurogenic bladder or before surgery where the diagnosis is uncertain.

Watchful waiting: appropriate for mild LUTS (IPSS 0-7) with no complications — lifestyle advice plus 6-12 monthly monitoring. Lifestyle modifications: reduce evening fluid intake (to limit nocturia), avoid caffeine and alcohol (bladder irritants), double-voiding technique, bladder training (progressive extension of voiding intervals for OAB symptoms), and weight loss (obesity worsens LUTS). Drug treatment — first-line: Alpha-blockers (tamsulosin 400 mcg once daily, alfuzosin, silodosin, doxazosin) — relax smooth muscle in the prostate and bladder neck within 48 hours; reduce IPSS by 30-40%; side effects — retrograde ejaculation, dizziness, postural hypotension. 5-Alpha-reductase inhibitors (finasteride 5mg or dutasteride 0.5mg daily) — block DHT production, shrink the prostate over 3-6 months (most effective for prostate volume above 30-40 mL); reduce prostate volume by 25-30%; prevent progression to AUR and surgery; side effects — erectile dysfunction, reduced libido, ejaculatory disorders (reversible on stopping). Combination therapy (alpha-blocker plus 5-ARI): more effective than monotherapy for men with moderate-severe LUTS and large prostate (MTOPS, CombAT trials). Anticholinergics/beta-3 agonists (mirabegron, solifenacin): for OAB-dominant storage symptoms in combination with or instead of alpha-blockers — avoid anticholinergics in men with high post-void residual (risk of precipitating urinary retention). Surgical options for moderate-severe LUTS not responding to medication or with complications: TURP (transurethral resection of the prostate — endoscopic removal of the obstructing tissue via the urethra; gold standard for prostates under 80-100 mL; expected improvement in Qmax of 100-160%); HoLEP (holmium laser enucleation of the prostate — effective for large prostates, low blood loss, shorter catheter time); UroLift (minimally invasive prostatic urethral lift — preserves ejaculatory function; suitable for men with moderate LUTS and smaller prostates); Rezum (water vapour thermal therapy). Acute urinary retention: emergency urethral or suprapubic catheterisation + alpha-blocker before trial without catheter (TWOC) at 48-72 hours.

Untreated urinary problems in men carry significant medical and quality-of-life complications. Benign prostatic hyperplasia (BPH) can progress to acute urinary retention (AUR) — sudden complete inability to pass urine despite a full bladder, causing severe suprapubic pain — an emergency requiring urethral catheterisation; AUR occurs in 2-3% of men with BPH per year and has a 50-70% recurrence rate without surgical treatment. Chronic urinary retention with overflow incontinence — painless bladder distension — causes high-pressure chronic retention leading to bilateral hydronephrosis, ureteral reflux, and progressive chronic kidney disease; unrecognised chronic retention can cause renal failure. Recurrent urinary tract infections from incomplete bladder emptying and stagnant residual urine cause urosepsis in severe cases. Bladder stones form from crystallisation of concentrated urine in chronically retained bladder — causing haematuria, pain, and further obstruction. Lower urinary tract symptoms (LUTS) severely impair quality of life — sleep disruption from nocturia, embarrassment from urgency incontinence, reduced social activities, depression, and sexual dysfunction are common. Untreated urethral stricture (from infection, catheterisation trauma, or hypospadias repair) progresses to complete obstruction requiring complex urethroplasty. New onset haematuria with LUTS must always prompt investigation to exclude bladder cancer or prostate cancer — delay in diagnosis directly worsens oncological outcomes.

While BPH is a natural consequence of ageing in most men and cannot be entirely prevented, progression of symptoms and complications can be delayed or prevented. Lifestyle measures that may reduce LUTS severity: regular physical activity (aerobic exercise — associated with lower LUTS severity in observational studies), healthy weight maintenance (obesity worsens LUTS and metabolic risk), and dietary choices (Mediterranean diet, reduced saturated fat, increased vegetables and omega-3 fatty acids — associated with lower BPH risk in some studies). Fluid management: maintain adequate hydration during the day (reducing fluid causes concentrated urine, which irritates the bladder); reduce fluid intake in the evening (3-4 hours before bedtime) to reduce nocturia. Caffeine and alcohol reduction: both act as bladder irritants and diuretics. Avoid medications that can precipitate or worsen LUTS: anticholinergics (antihistamines, some antidepressants), sympathomimetics (decongestants — pseudoephedrine). PSA testing awareness: men over 50 can request a PSA test from their GP (Prostate Cancer UK 'prostate check' programme) — this also detects prostate cancer at an earlier, more treatable stage.

See a GP for any new or worsening urinary symptoms — particularly if you are over 50. Symptoms requiring urgent same-day assessment: complete inability to urinate (acute urinary retention — a urological emergency requiring immediate catheterisation), blood in the urine (haematuria — haematuria without UTI always requires urgent urology referral to exclude bladder or kidney cancer), and urinary retention with overflow incontinence (constant dribbling, distended bladder). Seek urgent review within 2 weeks for: new LUTS with unexplained weight loss, bone pain, or elevated PSA (suspicion of prostate cancer); LUTS with features of UTI or pyelonephritis; and LUTS with deteriorating renal function (hydronephrosis from chronic urinary retention). Recurrent UTIs in a man always require urology investigation. Men should discuss PSA testing with their GP proactively from age 50 (or 45 if Black or with a family history of prostate cancer) — informed consent is essential before PSA testing.